danoprevir Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Danoprevir (INN) is an orally available 15-membered macrocyclic peptidomimetic inhibitor of NS3/4A HCV protease. It contains acylsulfonamide, fluoroisoindole and tert-butyl carbamate moieties. Danoprevir is a clinical candidate based on its favorable potency profile against multiple HCV genotypes 1–6 and key mutants (GT1b, IC50 = 0.2–0.4 nM; replicon GT1b, EC50 = 1.6 nM). Danoprevir has been evaluated in an open-label, single arm clinical trial in combination with ritonavir for treating COVID-19 and favourably compared to lopinavir/ritonavir in a second trial.   Wikipedia

Chemistry

  • SMILES: CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]3C[C@H](CN3C1=O)OC(=O)N4Cc5cccc(F)c5C4)C(=O)NS(=O)(=O)C6CC6
  • InChIKey: ZVTDLPBHTSMEJZ-JSZLBQEHSA-N
  • Mol. Mass: 731.84
  • ALogP: 3.14
  • ChEMBL Molecules:
    danoprevir  
    danoprevir  
More Chemistry

Pharmacology

Alternative names

danoprevir | itmn191 | itmn 191 | itmn-191 | r 7227 | r-7227 | r7227 cpd | rg7227 | rg 7227 | rg-7227 | ro5190591

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (1)


 

Hepatitis C

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

COVID-19 (Phase 4)

Healthy Volunteers (Phase 1)

Hepatitis C (Phase 2/Phase 3)

Hepatitis C, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 34
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue